Valerie Odegard, Ph.D., is a successful biotechnology executive with more than 15 years of experience in the development of immunotherapies to treat autoimmune/inflammatory disease, cancer and infectious disease. Valerie is currently the President and Chief Scientific Officer of Silverback Therapeutics ($SBTX), a clinical-stage biotechnology company developing tissue-targeted therapeutics. Previously, she was Vice President of R&D at Juno Therapeutics, where she was responsible for the development of novel cellular immunotherapies prior to Juno’s acquisition by Celgene. Valerie held leadership positions at Novo Nordisk and Trubion Pharmaceuticals, where she oversaw the development of therapeutics for oncology and inflammatory conditions. She received her Ph.D. in Immunobiology from Yale University.